| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary target of (±)-Pinoresinol is fungal pathogens, particularly Fusarium verticillioides. The compound exhibits potent antifungal activity with a MIC value of 1.0 mg/mL against F. verticillioides. As a lignan, it may exert its antifungal effects through disruption of fungal cell membranes or interference with fungal metabolic pathways. The compound does not have a defined receptor target but exerts its effects through direct antifungal mechanisms.
|
|---|---|
| ln Vitro |
(±)-Pinoresinol exhibits 1.0 mg/mL minimum inhibitory concentration (MIC) antifungal activity against Fusarium verticillioides [1].
In vitro, (±)-Pinoresinol demonstrates potent antifungal activity against Fusarium verticillioides with a MIC value of 1.0 mg/mL. The compound is a lignan and has been characterized for its antifungal properties. The antifungal activity is concentration-dependent and has been demonstrated in standard microbiological assays. |
| ln Vivo |
In vivo activity of (±)-Pinoresinol has not been extensively characterized. As a natural product with antifungal effects, it has potential for protecting against fungal infections. However, detailed in vivo pharmacokinetic and pharmacodynamic studies are limited. The compound is primarily studied for its antifungal properties in vitro.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (±)-Pinoresinol typically involve antifungal susceptibility testing. Fungal strains (e.g., Fusarium verticillioides) are cultured in appropriate media and treated with serial dilutions of the compound. The minimum inhibitory concentration (MIC) is determined after 24-48 hours of incubation at the appropriate temperature using the broth microdilution method. Cell viability is assessed by measuring optical density or by colony counting on agar plates. The compound demonstrates concentration-dependent antifungal activity.
|
| Cell Assay |
In vitro cellular assays for (±)-Pinoresinol involve testing its antifungal activity against fungal pathogens. Fungal cultures are grown in appropriate media and treated with serial dilutions of (±)-Pinoresinol (ranging from 0.1 to 10 mg/mL). After 24-48 hours of incubation, the optical density is measured to determine fungal growth inhibition. The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) are calculated from the dose-response curves. The compound shows concentration-dependent antifungal activity.
|
| Animal Protocol |
In vivo animal studies for (±)-Pinoresinol are limited, as the compound is primarily studied in vitro. For antifungal efficacy testing, animal models of fungal infection could be used. Animals would be treated with (±)-Pinoresinol via oral or topical administration, and fungal burden in target tissues would be assessed. However, detailed in vivo protocols are not well established in the available literature.
|
| ADME/Pharmacokinetics |
(±)-Pinoresinol has a molecular formula of C₂₀H₂₂O₆ and a molecular weight of 358.39. The compound appears as a solid with a purity of ≥98%. It is a lignan natural product with antifungal activity against Fusarium verticillioides. The compound is intended for research use only and has not been approved for clinical use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (±)-Pinoresinol has not been extensively characterized. As a natural product, it is generally considered to have low to moderate toxicity. Standard toxicity studies would include assessment of acute oral toxicity, dermal irritation, and repeated-dose toxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
4-[6-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofurano[3,4-c]furan-3-yl]-2-methoxyphenol has been reported in Daphne genkwa, Zanthoxylum simulans, and other organisms for which relevant data exist.
See also: Pinoresinol (note moved to). (±)-Pinoresinol (CAS 4263-88-1) is a lignan natural product with potent antifungal activity. It has a molecular formula of C₂₀H₂₂O₆ and a molecular weight of 358.39. The compound exhibits antifungal activity against Fusarium verticillioides with a MIC value of 1.0 mg/mL. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C20H22O6
|
|---|---|
| Molecular Weight |
358.39
|
| Exact Mass |
358.141
|
| CAS # |
4263-88-1
|
| PubChem CID |
234817
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
556.5±50.0 °C at 760 mmHg
|
| Melting Point |
144-145℃
|
| Flash Point |
290.4±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.598
|
| LogP |
1.54
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
431
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=CC(=C1)C2C3COC(C3CO2)C4=CC(=C(C=C4)O)OC)O
|
| InChi Key |
HGXBRUKMWQGOIE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H22O6/c1-23-17-7-11(3-5-15(17)21)19-13-9-26-20(14(13)10-25-19)12-4-6-16(22)18(8-12)24-2/h3-8,13-14,19-22H,9-10H2,1-2H3
|
| Chemical Name |
4-[6-(4-hydroxy-3-methoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7903 mL | 13.9513 mL | 27.9026 mL | |
| 5 mM | 0.5581 mL | 2.7903 mL | 5.5805 mL | |
| 10 mM | 0.2790 mL | 1.3951 mL | 2.7903 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
